In situ breast cancer incidence patterns in Iceland and differences in ductal carcinoma in situ treatment compared to Sweden

• Published in: Scientific Reports
• Main Authors: Agustsson, Arnar S., Birgisson, Helgi, Agnarsson, Bjarni A., Jonsson, Thorvaldur, Stefansdottir, Hrefna, Wärnberg, Fredrik, Lambe, Mats, Tryggvadottir, Laufey, Sverrisdottir, Asgerdur
• Format: Text
• Language: English
• Published: Nature Publishing Group UK 2020
• Subjects: Article; Iceland
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572374/; http://www.ncbi.nlm.nih.gov/pubmed/33077767; https://doi.org/10.1038/s41598-020-74134-5

The purpose was to review the incidence of in situ carcinoma in Iceland after initiating population-based mammography screening in 1987 and to compare management of ductal carcinoma in situ (DCIS) between Iceland and the Uppsala–Örebro region (UÖR) in Central Sweden. The Icelandic Cancer Registry provided data on in situ breast carcinomas for women between 1957 and 2017. Clinical data for women with DCIS between 2008 and 2014 was extracted from hospital records and compared to women diagnosed in UÖR. In Iceland, in situ carcinoma incidence increased from 7 to 30 per 100 000 women per year, following the introduction of organised mammography screening. The proportion of in situ carcinoma of all breast carcinomas increased from 4 to 12%. More than one third (35%) of women diagnosed with DCIS in Iceland were older than 70 years versus 18% in UÖR. In Iceland, 49% of all DCIS women underwent mastectomy compared to 40% in UÖR. The incidence of in situ carcinoma in Iceland increased four-fold after the uptake of population-based mammography screening causing considerable risk of overtreatment. Differences in treatment of DCIS were seen between Iceland and UÖR, revealing the importance of quality registration for monitoring patterns of management.